Table 1 Basic characteristics of control group and patients grouped by DanaPoint classification
From: The role of circulating thrombospondin-1 in patients with precapillary pulmonary hypertension
Control | All PH | PAH | LD | CTEPH | |
|---|---|---|---|---|---|
n | 19 | 93 (100) | 55 (59.1) | 22 (23.7) | 16 (17.2) |
Male | 7 | 37 | 19 | 15 | 3 |
Age [y] | 47.2 ± 14.9 | 59.3 ± 15.8* | 55.1 ± 16.9(*) | 66.9 ± 13.0*,** | 63.0 ± 9.9*,(**) |
Height [cm] | 169.2 ± 10.1 | 167.1 ± 9.8 | 165.6 ± 8.9 | 170.1 ± 11.9 | 168.4 ± 9.0 |
Weight [kg] | 71.7 ± 17.3 | 81.0 ± 20.0(*) | 81.6 ± 20.2 | 82.2 ± 23.7 | 76.8 ± 11.9 |
BSA [sqm] | 1.81 ± 0.23 | 1.89 ± 0.24 | 1.88 ± 0.23 | 1.92 ± 0.30 | 1.87 ± 0.17 |
FC II-III | 0 | 74 | 44 | 17 | 13 |
6MWD | 441 ± 68.4 | 328 ± 142* | 353 ± 110 | 243 ± 155*,** | 347 ± 192(***) |
PDEI | 0 | 43 (46.2) | 28 (51.0) | 11 (50.0) | 4 (25.0) |
ERA | 0 | 39 (41.9) | 29 (52.7) | 2 (9.1) | 8 (50.0) |
PC | 0 | 14 (15.1) | 12 (21.8) | 0 | 12 (12.5) |
Other | 0 | 6 (9.5) | 4 (10.8) | 2 (11.8) | 0 |
No drug | 16 (83.4) | 19 (20.4) | 6 (10.9) | 8 (36.4) | 5 (31.3) |
1 Drug | 3 (16.6) | 45 (48.4) | 26 (47.3) | 12 (54.5) | 7 (43.7) |
2 Drugs | 0 | 25 (26.9) | 19 (34.5) | 2 (9.1) | 4 (25.0) |
≥3 Drugs | 0 | 4 (4.3) | 4 (7.3) | 0 | 0 |